CLAIMS

1. A compound of Formula (I):



(I)

wherein

R^1, R^2, and R^3 are each independently hydrogen, hydroxy, halogen, optionally substituted C_{1-4} alkyl, optionally substituted C_{1-4} alkoxy, -CN, $-C(O)R^x$, $-C(O)OR^x$, $-S(O)_2R^x$, or $-NR^yR^z$;

R^x, R^y, and R^z are each independently H or optionally substituted C_{1-4}alkyl, or R^y and R^z taken together with the nitrogen to which they are attached form an optionally substituted monocyclic heterocycloalkyl ring;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is $–OCH_2CH_2$-O-CH_2CH_3 or $–OCH_2CH_2OCH_3$.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is $–NHCH_2CH_2OH$ or $-N(CH_2CH_3)_2$.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is morpholinyl, 4-methyl-piperazin-1-yl, piperidinyl, or pyrrolidinyl.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, C_{1-4} alkyl, or substituted C_{1-4} alkyl.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is CF_3.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is optionally substituted C_{1-4} alkoxy, -CN, or $-NR^yR^z$.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is $-N(CH_3)_2$.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is morpholinyl.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is methoxy, $–OCH_2CH_2$-O-CH_2CH_3, or $–OCH_2CH_2OCH_3$.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is halogen.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is chloro.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is methyl.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is –CN.

18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is morpholinyl.

19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-4} alkoxy.

20. The compound of claim 1, wherein the compound is selected from the group consisting of

Compound No.	**Structure**	**Name**
1		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
2		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-morpholinophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
3		4-(4-(phenylsulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
4		4-(4-((4-chlorophenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
5		4-(4-((4-chloro-3-methylphenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;

6		4-((4-(5-thioxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)sulfonyl)benzonitrile;
7		4-(4-((4-morpholinophenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
8		4-(4-((4-methoxyphenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
9		4-(4-tosylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
10		4-(4-((4-fluorophenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
11		4-(4-((3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;

12		4-(4-((3-methoxyphenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
13		4-(4-((3-(2-ethoxyethoxy)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
14		3-((4-(5-thioxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)sulfonyl)benzonitrile;
15		4-(4-((3-(dimethylamino)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
16		4-(4-((3-morpholinophenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
17		4-(4-(m-tolylsulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;

18		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-((2-hydroxyethyl)amino)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
19		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-(piperidin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
20		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-(4-methylpiperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
21		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-(diethylamino)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
22		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-(2-ethoxyethoxy)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;
23		4-(4-((4-methyl-3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione;

24		4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)-2-(pyrrolidin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione; and
25		4-(4-((3-(2-methoxyethoxy)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione,

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising (a) at least one compound of claim 1, or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable excipient.

24. The compound of any one of claims 1 to 23 for use in therapy.

25. Use of the compound of any one of claims 1 to 23 in the manufacture of a medicament for the treatment of any one of the following : Alzheimer's Disease, Parkinson's Disease, fronto-temporal dementia, dementia with Lewy Bodies, PD dementia, multiple system atrophy, Huntington's disease, Amyotrophic lateral sclerosis, progressive supranuclear palsy, infection, Crohn's disease, heart disease, aging, traumatic brain injury (TBI) and decreasing neuroinflammation, in a subject, wherein a therapeutically effective amount of the compound is to be administered to the subject.